Larimar Therapeutics (LRMR) stock rose after Oppenheimer issued an Outperform rating on the company, citing potential for its lead drug nomlabofusp. Read more here.
Oppenheimer has initiated coverage on Larimar Therapeutics, emphasizing its lead program Nomlabofusp as a transformative therapy for Friedreich's ataxia. With a price target of $26, the company plans ...
On Wednesday, Larimar Therapeutics Inc (LRMR) stock saw a modest uptick, ending the day at $7.71 which represents a slight increase of $0.29 or 3.91% from the prior close of $7.42. The stock opened at ...
On Thursday, Larimar Therapeutics (NASDAQ:LRMR) shares received an Outperform rating from Wedbush with a price target set at $22. The biopharmaceutical company, focused on the development of ...